Longboard announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). The analysis showed that bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures across the DEE study population. Longboard will rapidly advance bexicaserin's global Phase 3 trial.